Generate Biomedicines (NASDAQ:GENB) Shares Down 8.5% – Here’s What Happened

Generate Biomedicines Inc (NASDAQ:GENB) shares traded down 8.5% on Friday . The stock traded as low as $14.71 and last traded at $14.38. Approximately 86,802 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 701,000 shares. The stock had previously closed at $15.72.

Analysts Set New Price Targets

GENB has been the topic of several analyst reports. The Goldman Sachs Group assumed coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target on the stock. Morgan Stanley boosted their price objective on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Wall Street Zen lowered shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Guggenheim assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 target price on the stock. Finally, HC Wainwright lifted their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Performance

The company has a fifty day moving average price of $14.49. The company has a market cap of $1.83 billion and a P/E ratio of -13.32.

Generate Biomedicines (NASDAQ:GENB) last released its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.